Manhattan Scientifics (OTC; QB MHTX) announces its former wholly owned sub Imagion Bioscience (ASX:IBX) Receives A$2 million in R&D Tax Incentives from the Australian Government (ATO)
Bob Proulx, Executive Chairman of Imagion Biosystems, said: “We are very pleased to report to our shareholders that the tax incentive funds have been received and that the rebate came in higher than the A$1.7 million we originally expected. This cash infusion will significantly enhance our ability to advance the development of our ground-breaking diagnostic imaging technology which was recently designated by the U.S. Food and Drug Administration as a ‘Breakthrough Device’”.
About Manhattan Scientifics Inc.
Manhattan Scientifics is focused on the commercialization of disruptive technologies
Forward-looking statement:
This press release contains forward looking statements which are subject 5to a number of risks, assumptions and uncertainties. Mgt believes that purchase of our shares should be considered to be at the high end of the risk spectrum.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190725005680/en/
Contacts
Marvin Maslow, Chairman: 917.923.3300
Manny Tsoupanarias, CEO : 917.688.4158
Source: Manhattan Scientifics
View this news release online at:
http://www.businesswire.com/news/home/20190725005680/en
